Top Markets
Coin of the day
TetraLogic Pharmaceuticals Corporation TetraLogic Pharmaceuticals Corporation

TetraLogic Pharmaceuticals Corporation

TLOG
주식 순위 #42528
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage... TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
주가
$0.00004
마지막 동기화: 2026-08-11
시가총액
$979.00
변동 (1일)
0.00%
변동 (1년)
-60.00%
국가
US
거래 TetraLogic Pharmaceuticals Corporation (TLOG)

카테고리

TetraLogic Pharmaceuticals Corporation (TLOG)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
TetraLogic Pharmaceuticals Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
TetraLogic Pharmaceuticals Corporation의 P/S 비율 기록 (2026 ~ 2026)
매년 말 P/S 비율
연도 P/S 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/S 비율
회사 P/S 비율 P/S 비율 차이 국가
9.88 -
US
10.30 -
NL
- -
CH
4.98 -
BE
- -
KR